

Increase National Institutes of Health and National Cancer Institute Funding in FY2025

Cancer Research Delivers Breakthroughs & Hope



Increased and sustained investment at NIH and NCI in the fight against cancer year over year has been key to reducing the nation's cancer mortality rate by 30% since 1991, and will bring us closer to ending cancer as we know it, for everyone.

We can't afford to lose momentum.

2 Million+

New cancer cases projected in 2024 for the 1st time ever

611,720

estimated deaths due to cancer in 2024



Colorectal cancer diagnoses among people younger than 55

4

screenable cancers - breast, prostate, colorectal, and cervical - on the rise

18 Million+

cancer survivors in the U.S.

NIH and NCI Funding Drive U.S. Economic Growth

Investment fuels the U.S. economy and benefits every state and D.C.



In fiscal year 2023, NIH generated

\$92.89 Billion

in new economic activity nationwide

Return on Investment

\$1 in NIH funded research

=

\$2.46 in economic activity

supported

412,041

jobs

and

65,454

research grants

Demand for NCI Research

The growth of NCI R01 research grant applications over the last 10 years is almost

3x

that of the rest of NIH combined

5 out of **6**

researcher-initiated proposals go **unfunded** every year

NCI HAS

13%

LESS buying power than 20 years ago

Impact of Underinvestment

- ⚠️ Decline in applications funded
- ⚠️ Fewer opportunities for the next generation of researchers
- ⚠️ Reduced role of U.S. as the global leader in biomedical research
- ⚠️ Slower pace of breakthroughs in cancer prevention, screening, and treatment

FY 2025 NCI Scientific Opportunities


- Improving Patients’ Lives Through Symptom Science Research
- Revolutionizing Cancer Clinical Trials
- Clarifying the Impact of the Environment on Cancer Risk
- Harnessing the Power of Cancer Data
- Unraveling the Complexity of Cancer Metastasis

Recent NCI Milestones

- ✓ **First FDA-approved Treatment**
advanced cases of alveolar soft part sarcoma
- ✓ **Development of Drug Delivery Technology**
protecting drugs from the outside environment and guiding them directly to the target cancer cells
- ✓ **Overcoming Treatment Resistance**
identification of a drug that could be beneficial for ovarian cancer patients whose cancer has grown after treatment
- ✓ **Predicting Treatment Response**
identification of gene signatures associated with mesothelioma prognosis to help determine response to therapy

ACS CAN urges Congress to provide:

To ensure that the research being supported today yields the cancer treatments of tomorrow, Congress must sustain and expand the support it is currently providing.



[1] American Cancer Society. Cancer Facts and Figures 2024. Atlanta: American Cancer Society; 2024.
[2] United For Medical Research. 2024 Update NIH's Role in Sustaining the U.S. Economy. Retrieved on April 11, 2024, from: https://www.unitedformedicalresearch.org/wp-content/uploads/2023/03/UMR_NIHs-Role-in-Sustaining-the-U.S.-Economy-2023-Update.pdf
[3] National Cancer Institute: Annual Plan & Budget Proposal for Fiscal Year 2025. Retrieved on April 11, 2024, from: <https://www.cancer.gov/research/annual-plan/2024-annual-plan-budget-proposal-aag.pdf>
[4] CCR Milestones: Annual Highlights 2024. Retrieved on April 11, 2024, from: <https://ccr.cancer.gov/news/milestones-2024/flippingbook>